Hansdotter Oy

New venture capitalist will bring completely new service model to biotechnology and health technology growth companies

Share
The Nordic countries have a well-established tradition of making capital investments in early-stage growth companies in the ICT sector. In the field of biotechnology and health technology, however, venture capital investments have been significantly more difficult to obtain. Almaral, a new Finnish-based private equity investor, is a one-stop-shop for growth-minded Nordic biotech companies.

It is clear that there is a lack of angel investor capital in the biotech industry. Besides investments, early-stage biotech companies also need guidance in risk management, building up long-term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.

“Almaral is not your average venture capital company. We create value for our clients by answering the strategic and operational questions that a startup company can face in its early stages. Our team has excellent business knowledge and a solid understanding of the biotechnology industry. We have money, but we also know how to use it wisely. We have a unique network of partners and advisors to support our clients in their operational functions and to expand internationally,” says CEO Dr Maria Severina.

The investor team has exceptionally strong evidence of success

Almaral's investment partners have strong evidence of success in the internationally attractive biotech industry. In just a couple of decades, CEO Maria Severina managed to build HyTest into an international success story. Developing antibodies and antigens, the company grew from a two-person startup to one of Finland's most profitable companies. A year ago, HyTest was sold to Chinese Minday for hundreds of millions of euros. Chairman of the Board of Almaral

Alex Michine has been promoting future technologies for the global bioeconomy and has been an active spokesperson for the potential of cross-disciplinary collaboration. He has founded and successfully ran three biotech/cleantech SMEs, including since 2008, MetGen, which won the Frost and Sullivan European Industrial Enzymes Technology Innovation Award.

“We have been highly successful in our business. I believe the main reason for our success has been that we have focused on what we do best and have had the courage to trust good partners in many business support services. In addition to financing, we now want to offer this same model to our own customers,” says Severina.

Contact information:

Email: info@almaral.eu

For interviews: Maria Severina, +358405540127

Keywords

About Hansdotter Oy

Hansdotter Oy
Linnankatu 3
20100 TURKU

https://hansdotter.fi

Almaral invests in early-stage biotechnology and life sciences startups. Along with investments Almaral offers guidance in risk management, building up long term strategies, budgeting, setting up operational functions, legal support, setting up early-stage sales and marketing functions, and commercialization.

www.almaral.eu

Subscribe to releases from Hansdotter Oy

Subscribe to all the latest releases from Hansdotter Oy by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Hansdotter Oy

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye